Article
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2003
Geisler Stephanie, Børresen-Dale Anne-Lise, Johnsen Hilde, Aas Turid, Geisler Jürgen, Akslen Lars Andreas, Anker Gun, Lønning Per Eystein
Abstract excerpt
PURPOSE: Recent studies have found an association between certain TP53 mutations and resistance to anthracycline-based primary medical therapy in breast cancer. The purpose of this study was to investigate whether TP53 mutational status also might influence the response to a non-anthracycline-containing regimen in primary breast cancer. EXPERIMENTAL DESIGN: Thirty-five patients with locally advanced breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.